PMID- 22773213
OWN - NLM
STAT- MEDLINE
DCOM- 20130827
LR  - 20120709
IS  - 2078-2101 (Print)
IS  - 2078-2101 (Linking)
IP  - 12
DP  - 2012 Jul
TI  - Adult T-cell leukemia/lymphoma.
PG  - 27-37
AB  - The adult T-cell leukemia/lymphoma (ATLL) syndromes comprise neoplasms that arise 
      in peripheral lymphoid tissues but a high frequency present with blood 
      involvement mimicking T-cell leukemia. Clinically ATLL is sub-classified into 
      four groups: acute, lymphomatous, chronic and smoldering. ATLL is etiologically 
      linked to the human T-cell lymphotropic virus type I (HTLV-I). The diagnosis of 
      ATLL is based upon a combination of characteristic clinical manifestations, 
      morphological and immunophenotypic changes of the malignant cells, in addition to 
      the confirmation of HTLV-I infection. ATLL is an aggressive malignancy with a 
      median survival of less than 12 months and no successful treatment yet available. 
      Patients are either refractory or only transiently respond to chemotherapy or 
      purine analogues. Smoldering and chronic ATLL pursue an indolent course and 
      survival for years until the disease progresses and becomes refractory to 
      therapy. The major causes of death in ATLL are opportunistic pulmonary infections 
      and progressive disease, often in association with hypercalcemia.
FAU - Rasul, K I
AU  - Rasul KI
AD  - Al-Amal Hospital, Hamad Medical Corporation, Doha, Qatar. kakil954@yahoo.com
FAU - Barwari, Z A
AU  - Barwari ZA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Kuwait
TA  - Gulf J Oncolog
JT  - The Gulf journal of oncology
JID - 101500911
SB  - IM
MH  - Diagnosis, Differential
MH  - Humans
MH  - Leukemia-Lymphoma, Adult T-Cell/complications/diagnosis/*drug therapy/etiology
EDAT- 2012/07/10 06:00
MHDA- 2013/08/28 06:00
CRDT- 2012/07/10 06:00
PHST- 2012/06/17 00:00 [accepted]
PHST- 2012/07/10 06:00 [entrez]
PHST- 2012/07/10 06:00 [pubmed]
PHST- 2013/08/28 06:00 [medline]
PST - ppublish
SO  - Gulf J Oncolog. 2012 Jul;(12):27-37.